Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversation with Louise, he describes the unique challenges that market access leaders in the country are facing. 

Useful resources referenced in this podcast: 

March 2024 - Canadian Health Policy Institute (Patented Medicines Expenditure in Canada 1990 – 2022)

https://www.canadianhealthpolicy.com/product/patented-medicines-expenditure-in-canada-1990-2022-8th-edition/

January 2024 – Conference Board of Canada (Patented Medicines Expenditure in Canada 1990–2022 8TH Edition)

https://www.conferenceboard.ca/wp-content/uploads/2022/10/access-and-time-to-patient_jan2024.pdf

Innovative Medicines Canada – Access to Medicine

https://innovativemedicines.ca/browse-by/access-to-medicine/

April 2023 – Canadian Health Policy Journal (New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage)

https://www.canadianhealthpolicy.com/wp-content/uploads/2022/01/SKINNER-APR-23-New-cancer-drugs-in-Canada-2012-to-2021-final-1.pdf

April 2022 – Canadian Health Policy Institute (Access to New Medicines in Canada 2016 – 2021)

https://www.canadianhealthpolicy.com/posts/access-to-new-medicines-in-canada-2016-2021-federal-provincial-public-drug-programs-and-private-sector-drug-plans/

The opinions shared in this podcast are Sam’s own views and not representative of the company he is working for. 

Send us a text